{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:19:41Z","timestamp":1794345581132,"version":"4.9.0"},"reference-count":251,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG057522"],"award-info":[{"award-number":["R01 AG057522"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1 AG077695"],"award-info":[{"award-number":["RF1 AG077695"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R41 AG077992"],"award-info":[{"award-number":["R41 AG077992"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RF1-NS113548-01A1"],"award-info":[{"award-number":["RF1-NS113548-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtn.2025.102635","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T23:13:15Z","timestamp":1752793995000},"page":"102635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Boris","family":"Kantor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"O'Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornit","family":"Chiba-Falek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102635_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.omtn.2025.102635_bib2","article-title":"APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's","volume":"22","author":"Yang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102635_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-12-800149-3.00003-2","article-title":"Methods for gene transfer to the central nervous system","volume":"87","author":"Kantor","year":"2014","journal-title":"Adv. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","article-title":"The technological landscape and applications of single-cell multi-omics","volume":"24","author":"Baysoy","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102635_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800149-3.00002-0","article-title":"Clinical applications involving CNS gene transfer","volume":"87","author":"Kantor","year":"2014","journal-title":"Adv. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00148","article-title":"Gene-Editing Technologies Paired With Viral Vectors for Translational Research Into Neurodegenerative Diseases","volume":"13","author":"Rittiner","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1035543","article-title":"Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs","volume":"10","author":"Rittiner","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12033-024-01070-4","article-title":"The Future of Gene Therapy: A Review of In Vivo and Ex Vivo Delivery Methods for Genome Editing-Based Therapies","volume":"67","author":"Volodina","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omtn.2025.102635_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102635_bib11","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2217T to G\u2217C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly efficient Cas9-mediated transcriptional programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2025.102635_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50515-6","article-title":"The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders","volume":"15","author":"Kantor","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102635_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102084","article-title":"Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies","volume":"35","author":"Sun","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102635_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-024-07800-7","article-title":"A roadmap for affordable genetic medicines","volume":"634","author":"Kliegman","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","article-title":"CRISPR technologies for genome, epigenome and transcriptome editing","volume":"25","author":"Villiger","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102635_bib21","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","article-title":"CRISPR\/Cas9 Mediated Therapeutic Approach in Huntington's Disease","volume":"60","author":"Alkanli","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.omtn.2025.102635_bib22","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s13311-021-01081-y","article-title":"Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?","volume":"18","author":"Carpenter","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omtn.2025.102635_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/hum.2020.191","article-title":"Adeno-Associated Virus-Mediated Gene Therapy in the Mashlool, Atp1a3(Mashl\/+), Mouse Model of Alternating Hemiplegia of Childhood","volume":"32","author":"Hunanyan","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib24","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2025.102635_bib27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in vivo genome base editing in adult mice","volume":"24","author":"Villiger","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib28","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split-Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102635_bib29","article-title":"Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102635_bib30","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ymthe.2022.01.005","article-title":"A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver","volume":"30","author":"Zheng","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymthe.2021.07.011","article-title":"Dual-AAV delivering split prime editor system for in vivo genome editing","volume":"30","author":"Zhi","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib32","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/j.ymthe.2022.07.001","article-title":"A truncated reverse transcriptase enhances prime editing by split AAV vectors","volume":"30","author":"Gao","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","article-title":"Efficient prime editing in mouse brain, liver and heart with dual AAVs","volume":"42","author":"Davis","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib34","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.1073\/pnas.97.12.6716","article-title":"Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy","volume":"97","author":"Yan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102635_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/75087","article-title":"Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization","volume":"6","author":"Sun","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.omtm.2017.04.002","article-title":"Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR\/Cas9-Mediated Gene Editing","volume":"5","author":"Ortinski","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102635_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/mt.2010.277","article-title":"Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector","volume":"19","author":"Kantor","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib38","doi-asserted-by":"crossref","first-page":"18786","DOI":"10.1073\/pnas.0905859106","article-title":"Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection","volume":"106","author":"Kantor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102635_bib39","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.stem.2016.01.022","article-title":"CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs","volume":"18","author":"Mandegar","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrg.2016.28","article-title":"Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases","volume":"17","author":"Tsai","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0092-8674(83)90342-2","article-title":"Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV","volume":"33","author":"Samulski","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-2-43","article-title":"Adeno-associated virus: from defective virus to effective vector","volume":"2","author":"Goncalves","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.omtn.2025.102635_bib44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib45","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","article-title":"Immune responses to gene therapy vectors: influence on vector function and effector mechanisms","volume":"11","author":"Bessis","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib46","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nm901","article-title":"Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion","volume":"9","author":"Haberman","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/hum.2005.16.541","article-title":"Adeno-associated virus vectors in clinical trials","volume":"16","author":"Carter","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib48","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/jvi.34.2.402-409.1980","article-title":"Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA","volume":"34","author":"Lusby","year":"1980","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102635_bib49","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1073\/pnas.1001673107","article-title":"A viral assembly factor promotes AAV2 capsid formation in the nucleolus","volume":"107","author":"Sonntag","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102635_bib50","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/embo-reports\/kve234","article-title":"Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids","volume":"2","author":"Kronenberg","year":"2001","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omtn.2025.102635_bib51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/gt.2008.55","article-title":"Adeno-associated virus integration: virus versus vector","volume":"15","author":"Smith","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV Serotypes and Their Applications in Gene Therapy: An Overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102635_bib53","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.51","article-title":"Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna","volume":"1","author":"Hinderer","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102635_bib55","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1021\/acs.accounts.9b00277","article-title":"Achieving Spatial and Molecular Specificity with Ultrasound-Targeted Biomolecular Nanotherapeutics","volume":"52","author":"Szablowski","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omtn.2025.102635_bib56","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/v16030442","article-title":"Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights","volume":"16","author":"Lopez-Gordo","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102635_bib58","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors","volume":"12","author":"Buning","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102635_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cobme.2018.09.004","article-title":"Adeno-Associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering","volume":"7","author":"Lee","year":"2018","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"10.1016\/j.omtn.2025.102635_bib61","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/gt.2012.20","article-title":"Directed evolution of novel adeno-associated viruses for therapeutic gene delivery","volume":"19","author":"Bartel","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib62","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib63","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/hum.2019.186","article-title":"Ly6a Differential Expression in Blood-Brain Barrier Is Responsible for Strain Specific Central Nervous System Transduction Profile of AAV-PHP.B","volume":"31","author":"Batista","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib65","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ymthe.2019.02.016","article-title":"Neurotropic Properties of AAV-PHP.B Are Shared among Diverse Inbred Strains of Mice","volume":"27","author":"Matsuzaki","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41596-018-0097-3","article-title":"Systemic AAV vectors for widespread and targeted gene delivery in rodents","volume":"14","author":"Challis","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2025.102635_bib67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib68","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41565-023-01419-x","article-title":"Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain","volume":"18","author":"Chuapoco","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib69","doi-asserted-by":"crossref","first-page":"609","DOI":"10.15252\/emmm.201506078","article-title":"A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases","volume":"8","author":"Korbelin","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib70","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.neuron.2016.09.021","article-title":"A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons","volume":"92","author":"Tervo","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2025.102635_bib71","article-title":"Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib72","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrmicro1793","article-title":"CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea","volume":"6","author":"Sorek","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.omtn.2025.102635_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001481","article-title":"Evolutionary plasticity and functional versatility of CRISPR systems","volume":"20","author":"Koonin","year":"2022","journal-title":"PLoS Biol."},{"key":"10.1016\/j.omtn.2025.102635_bib75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mib.2017.05.008","article-title":"Diversity, classification and evolution of CRISPR-Cas systems","volume":"37","author":"Koonin","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.omtn.2025.102635_bib76","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature09886","article-title":"CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III","volume":"471","author":"Deltcheva","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib77","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib78","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1021\/acs.biochem.3c00159","article-title":"Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox","volume":"62","author":"Koonin","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.omtn.2025.102635_bib79","series-title":"Methods in iPSC Technology","first-page":"79","article-title":"Chapter 4 - Lentiviral vectors as the delivery vehicles for transduction into iPSCs: shortcomings and benefits","author":"Kantor","year":"2021"},{"key":"10.1016\/j.omtn.2025.102635_bib80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrmicro3569","article-title":"An updated evolutionary classification of CRISPR-Cas systems","volume":"13","author":"Makarova","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.omtn.2025.102635_bib81","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41579-019-0299-x","article-title":"Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants","volume":"18","author":"Makarova","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.omtn.2025.102635_bib82","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2025.102635_bib83","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature14592","article-title":"Engineered CRISPR-Cas9 nucleases with altered PAM specificities","volume":"523","author":"Kleinstiver","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib84","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2016.01.039","article-title":"Structure and Engineering of Francisella novicida Cas9","volume":"164","author":"Hirano","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib85","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aba8853","article-title":"Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants","volume":"368","author":"Walton","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib86","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib87","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib88","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature24268","article-title":"Enhanced proofreading governs CRISPR-Cas9 targeting accuracy","volume":"550","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib89","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1318-8","article-title":"Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage","volume":"18","author":"Kulcsar","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.omtn.2025.102635_bib90","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib91","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41587-019-0095-1","article-title":"Increasing the specificity of CRISPR systems with engineered RNA secondary structures","volume":"37","author":"Kocak","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib92","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib93","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.omtn.2017.05.009","article-title":"Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1","volume":"8","author":"Yang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102635_bib94","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nbt.3620","article-title":"Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells","volume":"34","author":"Kleinstiver","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202200032","article-title":"Prime editing in plants and mammalian cells: Mechanism, achievements, limitations, and future prospects","volume":"44","author":"Hillary","year":"2022","journal-title":"Bioessays"},{"key":"10.1016\/j.omtn.2025.102635_bib96","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41589-021-00868-6","article-title":"Programmed genome editing by a miniature CRISPR-Cas12f nuclease","volume":"17","author":"Wu","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.omtn.2025.102635_bib97","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1126\/science.aax9181","article-title":"RNA-guided DNA insertion with CRISPR-associated transposases","volume":"365","author":"Strecker","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib98","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1016\/j.molcel.2022.11.003","article-title":"The miniature CRISPR-Cas12m effector binds DNA to block transcription","volume":"82","author":"Wu","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib99","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.abb1400","article-title":"CRISPR-CasPhi from huge phages is a hypercompact genome editor","volume":"369","author":"Pausch","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41422-022-00771-2","article-title":"The compact Caspi (Cas12l) 'bracelet' provides a unique structural platform for DNA manipulation","volume":"33","author":"Sun","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.omtn.2025.102635_bib101","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1016\/j.cell.2022.10.020","article-title":"Diverse virus-encoded CRISPR-Cas systems include streamlined genome editors","volume":"185","author":"Al-Shayeb","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib102","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.molcel.2023.06.014","article-title":"Cas12n nucleases, early evolutionary intermediates of type V CRISPR, comprise a distinct family of miniature genome editors","volume":"83","author":"Chen","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib103","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41586-021-04058-1","article-title":"Transposon-associated TnpB is a programmable RNA-guided DNA endonuclease","volume":"599","author":"Karvelis","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib104","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/JB.00783-15","article-title":"ISC, a Novel Group of Bacterial and Archaeal DNA Transposons That Encode Cas9 Homologs","volume":"198","author":"Kapitonov","year":"2015","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.omtn.2025.102635_bib105","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41586-023-06356-2","article-title":"Fanzor is a eukaryotic programmable RNA-guided endonuclease","volume":"620","author":"Saito","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib106","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1021\/acschembio.4c00247","article-title":"Miniature CRISPR-Cas12 Systems: Mechanisms, Engineering, and Genome Editing Applications","volume":"19","author":"Tang","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.omtn.2025.102635_bib107","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature19802","article-title":"Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection","volume":"538","author":"East-Seletsky","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib108","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2016.12.031","article-title":"Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities","volume":"168","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib109","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib110","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","article-title":"Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents","volume":"39","author":"Blanchard","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16731-6","article-title":"Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria","volume":"11","author":"Kiga","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102635_bib112","article-title":"The CRISPR-Cas13a Gene-Editing System Induces Collateral Cleavage of RNA in Glioma Cells","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2025.102635_bib113","first-page":"1559","article-title":"Genome editing: A perspective on the application of CRISPR\/Cas9 to study human diseases (Review)","volume":"43","author":"Rodriguez-Rodriguez","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib114","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib115","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102635_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/nrg.2017.1","article-title":"Metagenomics: Uncultivated microbes reveal new CRISPR-Cas systems","volume":"18","author":"Cloney","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib117","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature21059","article-title":"New CRISPR-Cas systems from uncultivated microbes","volume":"542","author":"Burstein","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib118","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04048-4","article-title":"RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors","volume":"9","author":"Thakore","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102635_bib119","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","article-title":"Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?","volume":"6","author":"Keeler","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omtn.2025.102635_bib120","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nbt1117-998","article-title":"First AAV gene therapy poised for landmark approval","volume":"35","author":"Smalley","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib121","article-title":"FDA new drug approvals in Q2 2019","volume":"18","author":"Urquhart","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102635_bib122","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-020-00413-4","article-title":"APOE2: protective mechanism and therapeutic implications for Alzheimer's disease","volume":"15","author":"Li","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.omtn.2025.102635_bib123","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102635_bib124","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.mce.2006.03.013","article-title":"Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study","volume":"252","author":"Backman","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.omtn.2025.102635_bib125","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2025.102635_bib126","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41434-022-00346-1","article-title":"Assessment of AAV9 distribution and transduction in rats after administration through Intrastriatal, Intracisterna magna and Lumbar Intrathecal routes","volume":"30","author":"Chandran","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12121216","article-title":"Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB","volume":"12","author":"Kimura","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102635_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102725","article-title":"Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases","volume":"11","author":"Li","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102635_bib129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nm1398","article-title":"Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer","volume":"12","author":"Brown","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib130","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/nbt1372","article-title":"Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state","volume":"25","author":"Brown","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102635_bib131","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/gt.2010.157","article-title":"Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver","volume":"18","author":"Qiao","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib132","article-title":"AAV Targeting of Glial Cell Types in the Central and Peripheral Nervous System and Relevance to Human Gene Therapy","volume":"13","author":"O'Carroll","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib133","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/glia.20795","article-title":"Engineered lentiviral vector targeting astrocytes in vivo","volume":"57","author":"Colin","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.omtn.2025.102635_bib134","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer's disease facts and figures","volume":"18","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.omtn.2025.102635_bib135","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-017-0475-z","article-title":"CRISPR\/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 (N141I) neurons","volume":"5","author":"Ortiz-Virumbrales","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.omtn.2025.102635_bib136","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04238-0","article-title":"Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology","volume":"9","author":"Nagata","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102635_bib137","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib138","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib139","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/JAD-2010-1212","article-title":"Genome-Wide Scan of Copy Number Variation in Late-Onset Alzheimer's Disease","volume":"19","author":"Heinzen","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.omtn.2025.102635_bib140","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/mp.2011.135","article-title":"Genome-wide association analysis of age-at-onset in Alzheimer's disease","volume":"17","author":"Kamboh","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.omtn.2025.102635_bib141","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.45","article-title":"Genome-wide association study of Alzheimer's disease","volume":"2","author":"Kamboh","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.omtn.2025.102635_bib142","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1001\/jama.2010.574","article-title":"Genome-wide analysis of genetic loci associated with Alzheimer disease","volume":"303","author":"Seshadri","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102635_bib143","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib144","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib145","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4088\/JCP.v68n0419","article-title":"A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease","volume":"68","author":"Coon","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.omtn.2025.102635_bib146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047760","article-title":"The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes)","volume":"7","author":"McIntosh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102635_bib147","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance","volume":"3","author":"Castellano","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib148","article-title":"Lentiviral vector platform for the efficient delivery of epigenome-editing tools into human induced pluripotent stem cell-derived disease models","volume":"145","author":"Tagliafierro","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omtn.2025.102635_bib149","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0065-2660(07)00414-2","article-title":"Haplotype-association analysis","volume":"60","author":"Liu","year":"2008","journal-title":"Adv. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib151","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.90.20.9649","article-title":"Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease","volume":"90","author":"Schmechel","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102635_bib152","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","article-title":"Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease","volume":"43","author":"Saunders","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102635_bib153","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jama.2013.3507","article-title":"Genome-wide association studies, Alzheimer disease, and understudied populations","volume":"309","author":"Nussbaum","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102635_bib154","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","article-title":"APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease","volume":"30","author":"Fortea","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib155","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0460.1000209","article-title":"The Role of Upregulated APOE in Alzheimer's Disease Etiology","volume":"6","author":"Gottschalk","year":"2016","journal-title":"J. Alzheimers Dis. Parkinsonism"},{"key":"10.1016\/j.omtn.2025.102635_bib156","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cell.2016.12.044","article-title":"ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion","volume":"168","author":"Huang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102635_bib157","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1523\/JNEUROSCI.0260-15.2015","article-title":"ApoE4 and Abeta Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation","volume":"35","author":"Sen","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib158","doi-asserted-by":"crossref","first-page":"18303","DOI":"10.1073\/pnas.1314145110","article-title":"Neuroprotective Sirtuin ratio reversed by ApoE4","volume":"110","author":"Theendakara","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102635_bib159","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1523\/JNEUROSCI.3562-15.2016","article-title":"Direct Transcriptional Effects of Apolipoprotein E","volume":"36","author":"Theendakara","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib160","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2025.102635_bib161","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15252\/embr.201540614","article-title":"ApoE4 upregulates the activity of mitochondria-associated ER membranes","volume":"17","author":"Tambini","year":"2016","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omtn.2025.102635_bib162","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jmb.2006.06.080","article-title":"Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils","volume":"361","author":"Hatters","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102635_bib163","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1002\/alz.13867","article-title":"Proteins linking APOE varepsilon4 with Alzheimer's disease","volume":"20","author":"Oveisgharan","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.omtn.2025.102635_bib164","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","article-title":"Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of beta-amyloidosis","volume":"96","author":"Huynh","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2025.102635_bib165","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1084\/jem.20121274","article-title":"Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis","volume":"209","author":"Kim","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib166","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","article-title":"Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis","volume":"34","author":"Liao","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib167","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/1567205013666160404120817","article-title":"An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo","volume":"13","author":"Luz","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.omtn.2025.102635_bib168","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI96429","article-title":"Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation","volume":"128","author":"Liao","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102635_bib169","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib170","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.neuron.2024.01.008","article-title":"APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's disease pathology","volume":"112","author":"Chemparathy","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2025.102635_bib171","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.omtn.2025.102635_bib172","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s43587-021-00117-4","article-title":"Dissociable effects of APOE-epsilon4 and beta-amyloid pathology on visual working memory","volume":"1","author":"Lu","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.omtn.2025.102635_bib173","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-66114-6","article-title":"Short-term memory advantage for brief durations in human APOE epsilon4 carriers","volume":"10","author":"Zokaei","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102635_bib174","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1016\/j.ymthe.2024.11.003","article-title":"AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer's disease mice","volume":"32","author":"Gunaydin","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib175","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-024-00793-x","article-title":"APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology","volume":"20","author":"Tran","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.omtn.2025.102635_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2018.05.008","article-title":"APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types","volume":"98","author":"Lin","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2025.102635_bib177","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","article-title":"Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector","volume":"24","author":"Wang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102635_bib178","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1093\/hmg\/ddu196","article-title":"The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease","volume":"23","author":"Linnertz","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib179","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jalz.2015.05.011","article-title":"A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression","volume":"11","author":"Lutz","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.omtn.2025.102635_bib180","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/mds.10559","article-title":"Clinical overview of the synucleinopathies","volume":"18","author":"Marti","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2025.102635_bib181","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: clinical and pathological implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.omtn.2025.102635_bib182","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1353-8020(99)00031-0","article-title":"Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies","volume":"5","author":"Spillantini","year":"1999","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.omtn.2025.102635_bib183","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.10557","article-title":"Neuropathological spectrum of synucleinopathies","volume":"18","author":"Jellinger","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2025.102635_bib184","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.biochem.74.082803.133400","article-title":"The biochemistry of Parkinson's disease","volume":"74","author":"Cookson","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omtn.2025.102635_bib186","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1087753","article-title":"Molecular pathways of neurodegeneration in Parkinson's disease","volume":"302","author":"Dawson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib187","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.omtn.2025.102635_bib188","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00415-014-7439-z","article-title":"Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia","volume":"261","author":"Grothe","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.omtn.2025.102635_bib189","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awu193","article-title":"Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease","volume":"137","author":"Hall","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2025.102635_bib190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-510X(02)00006-0","article-title":"Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies","volume":"195","author":"Marui","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omtn.2025.102635_bib191","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","article-title":"Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction","volume":"117","author":"Beach","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtn.2025.102635_bib192","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00439-008-0582-9","article-title":"Genomewide association study for susceptibility genes contributing to familial Parkinson disease","volume":"124","author":"Pankratz","year":"2009","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib193","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0404.2008.01019.x","article-title":"Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population","volume":"118","author":"Myhre","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.omtn.2025.102635_bib194","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.mad.2007.04.002","article-title":"Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease","volume":"128","author":"Ross","year":"2007","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.omtn.2025.102635_bib195","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.20268","article-title":"alpha-Synuclein promoter confers susceptibility to Parkinson's disease","volume":"56","author":"Pals","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102635_bib196","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.20438","article-title":"Multiple regions of alpha-synuclein are associated with Parkinson's disease","volume":"57","author":"Mueller","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102635_bib197","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/hmg\/ddl030","article-title":"Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease","volume":"15","author":"Mizuta","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib198","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1212\/01.wnl.0000275524.15125.f4","article-title":"alpha-Synuclein and Parkinson disease susceptibility","volume":"69","author":"Winkler","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102635_bib199","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ng.485","article-title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease","volume":"41","author":"Satake","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib200","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Simon-Sanchez","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1469-1809.2009.00560.x","article-title":"Genome-Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease","volume":"74","author":"Edwards","year":"2010","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib202","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.296.6.661","article-title":"Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease","volume":"296","author":"Maraganore","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102635_bib203","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/ddq469","article-title":"Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21","volume":"20","author":"UK Parkinson's Disease Consortium","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib204","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/ejhg.2010.254","article-title":"Genome-wide association study confirms extant PD risk loci among the Dutch","volume":"19","author":"Simon-Sanchez","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib205","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/archneurol.2010.279","article-title":"SNCA variant associated with Parkinson disease and plasma alpha-synuclein level","volume":"67","author":"Mata","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.omtn.2025.102635_bib206","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib207","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1093\/hmg\/ddu334","article-title":"Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies","volume":"23","author":"Bras","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102635_bib208","article-title":"Dopamine Cytotoxicity Involves Both Oxidative and Nonoxidative Pathways in SH-SY5Y Cells: Potential Role of Alpha-Synuclein Overexpression and Proteasomal Inhibition in the Etiopathogenesis of Parkinson's Disease","volume":"2014","author":"Banerjee","year":"2014","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.omtn.2025.102635_bib209","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1471-4159.2009.06054.x","article-title":"Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death","volume":"109","author":"Vekrellis","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.omtn.2025.102635_bib210","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0006-8993(00)02215-0","article-title":"Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells","volume":"866","author":"Zhou","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.omtn.2025.102635_bib211","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089327","article-title":"Differential expression of alpha-synuclein in hippocampal neurons","volume":"9","author":"Taguchi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102635_bib212","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.169","article-title":"Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons","volume":"6","author":"Koch","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2025.102635_bib213","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0304-3940(02)00016-2","article-title":"Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine","volume":"320","author":"Junn","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.omtn.2025.102635_bib214","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1453","article-title":"Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus","volume":"2","author":"Devine","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102635_bib215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026159","article-title":"SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress","volume":"6","author":"Byers","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102635_bib216","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11910-012-0270-y","article-title":"Modeling Parkinson's disease using induced pluripotent stem cells","volume":"12","author":"Byers","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.omtn.2025.102635_bib217","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112413","article-title":"Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication","volume":"9","author":"Flierl","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102635_bib218","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s13311-013-0234-1","article-title":"Animal models of Parkinson's disease: a gateway to therapeutics?","volume":"11","author":"Le","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omtn.2025.102635_bib219","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1471-4159.2003.01809.x","article-title":"Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein","volume":"86","author":"Lakso","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.omtn.2025.102635_bib220","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/35006074","article-title":"A Drosophila model of Parkinson's disease","volume":"404","author":"Feany","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102635_bib221","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1471-4159.2004.02728.x","article-title":"Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease","volume":"91","author":"Yamada","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.omtn.2025.102635_bib222","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib223","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.mcn.2011.11.006","article-title":"Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression","volume":"49","author":"McLean","year":"2012","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib224","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.nbd.2014.06.017","article-title":"Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein","volume":"70","author":"Subramaniam","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtn.2025.102635_bib225","doi-asserted-by":"crossref","first-page":"E4016","DOI":"10.1073\/pnas.1309143110","article-title":"Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model","volume":"110","author":"Janezic","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102635_bib226","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1073\/pnas.0536383100","article-title":"Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease","volume":"100","author":"Kirik","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102635_bib227","doi-asserted-by":"crossref","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102635_bib228","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1212\/01.wnl.0000254458.17630.c5","article-title":"Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication","volume":"68","author":"Fuchs","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102635_bib229","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.21380","article-title":"Genomic investigation of alpha-synuclein multiplication and parkinsonism","volume":"63","author":"Ross","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102635_bib230","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102635_bib231","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","article-title":"Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease","volume":"364","author":"Ibanez","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102635_bib232","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10846","article-title":"Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications","volume":"55","author":"Farrer","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102635_bib233","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1212\/01.WNL.0000127517.33208.F4","article-title":"Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication","volume":"62","author":"Miller","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102635_bib234","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10048-016-0478-0","article-title":"Up-regulation of SNCA gene expression: implications to synucleinopathies","volume":"17","author":"Tagliafierro","year":"2016","journal-title":"Neurogenetics"},{"key":"10.1016\/j.omtn.2025.102635_bib235","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/mds.21007","article-title":"Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients","volume":"21","author":"Chiba-Falek","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2025.102635_bib236","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkn084","article-title":"Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease","volume":"36","author":"Grundemann","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102635_bib237","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0006-8993(01)02772-X","article-title":"Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease","volume":"914","author":"Rockenstein","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.omtn.2025.102635_bib238","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012122","article-title":"Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra","volume":"5","author":"McCormack","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102635_bib239","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.14","article-title":"Normalization of Overexpressed alpha-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference","volume":"4","author":"Takahashi","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102635_bib240","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib241","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2011.04.036","article-title":"An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons","volume":"1395","author":"Khodr","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.omtn.2025.102635_bib242","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2017.04.004","article-title":"Deregulation of alpha-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA","volume":"154","author":"Guhathakurta","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.omtn.2025.102635_bib243","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","article-title":"Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains","volume":"30","author":"Jowaed","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib244","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cns.12059","article-title":"A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons","volume":"19","author":"Wang","year":"2013","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.omtn.2025.102635_bib245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015522","article-title":"CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease","volume":"5","author":"Matsumoto","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102635_bib246","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.652226","article-title":"Cell-Type Specific Changes in DNA Methylation of SNCA Intron 1 in Synucleinopathy Brains","volume":"15","author":"Gu","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtn.2025.102635_bib247","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41592-018-0048-5","article-title":"An enhanced CRISPR repressor for targeted mammalian gene regulation","volume":"15","author":"Yeo","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2025.102635_bib248","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102635_bib249","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.expneurol.2017.04.008","article-title":"Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes","volume":"298","author":"Scott","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtn.2025.102635_bib250","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MS9.0000000000001500","article-title":"Application of CRISPR\/Cas9 in the management of Alzheimer's disease and Parkinson's disease: a review","volume":"86","author":"Thapar","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.omtn.2025.102635_bib251","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/crispr.2021.0025","article-title":"CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo","volume":"5","author":"Yoon","year":"2022","journal-title":"CRISPR J."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:07:44Z","timestamp":1781212064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":251,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2162253125001891"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102635","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102635"}}